Allergan PE Ratio 2006-2018 | AGN

Current and historical p/e ratio for Allergan (AGN) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Allergan PE ratio as of October 19, 2018 is 11.04.
Allergan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-10-19 189.53 0.00
2018-06-30 166.07 $-5.57 0.00
2018-03-31 166.88 $-6.55 0.00
2017-12-31 161.49 $-13.42 0.00
2017-09-30 201.52 $-22.50 0.00
2017-06-30 238.29 $28.15 8.47
2017-03-31 233.48 $29.08 8.03
2016-12-31 204.64 $37.41 5.47
2016-09-30 224.42 $35.83 6.26
2016-06-30 225.18 $10.54 21.36
2016-03-31 261.18 $11.18 23.36
2015-12-31 304.51 $8.86 34.37
2015-09-30 264.86 $7.88 33.61
2015-06-30 295.70 $-9.36 0.00
2015-03-31 290.01 $-8.28 0.00
2014-12-31 250.83 $-5.88 0.00
2014-09-30 235.11 $-3.98 0.00
2014-06-30 217.35 $0.46 472.49
2014-03-31 200.59 $-4.09 0.00
2013-12-31 163.70 $-5.43 0.00
2013-09-30 140.28 $-4.36 0.00
2013-06-30 122.91 $-4.25 0.00
2013-03-31 89.69 $-0.47 0.00
2012-12-31 83.74 $0.75 111.66
2012-09-30 82.93 $1.29 64.28
2012-06-30 72.05 $1.23 58.58
2012-03-31 65.30 $2.14 30.51
2011-12-31 58.76 $2.07 28.39
2011-09-30 66.46 $1.47 45.21
2011-06-30 66.93 $1.14 58.71
2011-03-31 54.54 $1.29 42.28
2010-12-31 50.30 $1.50 33.53
2010-09-30 41.20 $1.86 22.15
2010-06-30 39.51 $2.19 18.04
2010-03-31 40.67 $2.07 19.65
2009-12-31 38.57 $1.93 19.99
2009-09-30 35.68 $1.92 18.58
2009-06-30 32.81 $2.00 16.40
2009-03-31 30.29 $2.08 14.56
2008-12-31 25.87 $2.10 12.32
2008-09-30 27.75 $1.94 14.31
2008-06-30 26.46 $1.63 16.23
2008-03-31 28.55 $1.43 19.97
2007-12-31 26.43 $1.27 20.81
2007-09-30 31.55 $-3.87 0.00
2007-06-30 31.68 $-3.87 0.00
2007-03-31 25.74 $-4.33 0.00
2006-12-31 25.35 $-4.39 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $64.335B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Versartis (ARAV) United States $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00